Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Viemed Healthcare (VMD) EBIT (2018 - 2026)

Viemed Healthcare filings provide 8 years of EBIT readings, the most recent being $8.4 million for Q4 2025.

  • On a quarterly basis, EBIT rose 29.74% to $8.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $22.9 million, a 28.21% increase, with the full-year FY2025 number at $22.9 million, up 28.21% from a year prior.
  • EBIT hit $8.4 million in Q4 2025 for Viemed Healthcare, up from $5.6 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $8.4 million in Q4 2025 to a low of $1.0 million in Q2 2022.
  • Median EBIT over the past 5 years was $3.6 million (2022), compared with a mean of $3.8 million.
  • Biggest five-year swings in EBIT: tumbled 79.28% in 2021 and later skyrocketed 189.81% in 2023.
  • Viemed Healthcare's EBIT stood at $4.7 million in 2021, then decreased by 24.24% to $3.5 million in 2022, then surged by 49.66% to $5.3 million in 2023, then rose by 21.99% to $6.5 million in 2024, then increased by 29.74% to $8.4 million in 2025.
  • The last three reported values for EBIT were $8.4 million (Q4 2025), $5.6 million (Q3 2025), and $5.1 million (Q2 2025) per Business Quant data.